Compare Magna International Inc. Common Stock (MGA) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Magna International Inc. Common Stock vs Natera Inc. Common Stock — how do they compare? Magna International Inc. Common Stock trades at $64.38 (market cap $17.39B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 3.3× Magna International Inc. Common Stock's market cap, and Magna International Inc. Common Stock pays a 3.03% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Magna International Inc. Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| MGA | NTRA | |
|---|---|---|
Market Cap | $17.39B | $57.03B |
Volume | 1,279,527 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $73.05 | $425.64 |
52-Week Low | $44.65 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $22.42B | $56.18B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Magna International (MGA) trades at $65.31, up 2.75% with a bullish technical signal. The stock shows strong earnings momentum with three consecutive quarterly beats and trades at attractive valuations with P/E of 24.01 and P/S of 0.43. Recent news highlights margin expansion and international growth opportunities, while cash flow remains positive despite increased capital returns.
MGA presents a favorable risk-reward profile with analyst consensus target of $69.20 (5.9% upside) and 43% buy ratings. Key catalysts include Q3 2026 earnings on October 30 and continued margin improvement, though risks include flat auto production and potential tariff impacts on North American operations.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Magna International Inc. Common Stock
Magna International Inc. is a Canada-based automotive supplier that designs, engineers, and manufactures vehicle systems and components, including body and chassis structures, seating, powertrain, and electronics, and provides complete-vehicle engineering and contract assembly, with manufacturing operations in 28 countries.
Read more on MGA →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
